Los Angeles Capital Management & Equity Research Inc. cut its position in Emergent Biosolutions Inc (NYSE:EBS) by 6.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,639 shares of the biopharmaceutical company’s stock after selling 1,772 shares during the quarter. Los Angeles Capital Management & Equity Research Inc.’s holdings in Emergent Biosolutions were worth $1,819,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the stock. Family Firm Inc. bought a new position in Emergent Biosolutions during the third quarter worth $225,000. Everence Capital Management Inc. bought a new position in Emergent Biosolutions during the third quarter worth $261,000. Thompson Siegel & Walmsley LLC bought a new position in Emergent Biosolutions during the second quarter worth $202,000. Sun Life Financial INC bought a new position in Emergent Biosolutions during the second quarter worth $234,000. Finally, Intrust Bank NA bought a new position in Emergent Biosolutions during the second quarter worth $234,000. 82.23% of the stock is owned by institutional investors and hedge funds.

A number of research firms have commented on EBS. Zacks Investment Research reaffirmed a “hold” rating on shares of Emergent Biosolutions in a research report on Tuesday, November 13th. Argus set a $80.00 price objective on shares of Emergent Biosolutions and gave the stock a “buy” rating in a research report on Friday, November 9th. Cantor Fitzgerald lifted their price objective on shares of Emergent Biosolutions from $68.00 to $75.00 and gave the stock an “overweight” rating in a research report on Friday, November 2nd. Goldman Sachs Group raised Emergent Biosolutions from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $60.00 to $75.00 in a report on Friday, November 2nd. Finally, Chardan Capital lifted their target price on Emergent Biosolutions from $60.00 to $66.00 and gave the stock a “buy” rating in a report on Tuesday, September 4th. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $66.25.

In related news, CEO Daniel Abdun-Nabi sold 90,776 shares of the business’s stock in a transaction dated Wednesday, September 5th. The stock was sold at an average price of $60.18, for a total value of $5,462,899.68. Following the completion of the transaction, the chief executive officer now owns 257,343 shares of the company’s stock, valued at $15,486,901.74. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Kathryn C. Zoon sold 4,242 shares of the business’s stock in a transaction dated Wednesday, November 7th. The shares were sold at an average price of $69.74, for a total value of $295,837.08. Following the completion of the transaction, the director now directly owns 33,972 shares of the company’s stock, valued at approximately $2,369,207.28. The disclosure for this sale can be found here. Insiders have sold 155,732 shares of company stock valued at $9,608,408 in the last three months. Insiders own 13.40% of the company’s stock.

EBS opened at $69.70 on Tuesday. Emergent Biosolutions Inc has a fifty-two week low of $37.13 and a fifty-two week high of $71.77. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.52 and a quick ratio of 4.29. The firm has a market cap of $3.63 billion, a PE ratio of 36.68, a PEG ratio of 1.80 and a beta of 1.27.

Emergent Biosolutions (NYSE:EBS) last posted its earnings results on Thursday, November 1st. The biopharmaceutical company reported $0.55 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.62 by ($0.07). Emergent Biosolutions had a return on equity of 12.89% and a net margin of 14.19%. The firm had revenue of $173.70 million for the quarter, compared to analyst estimates of $185.16 million. During the same period in the prior year, the business posted $0.73 EPS. The firm’s quarterly revenue was up 16.3% compared to the same quarter last year. On average, sell-side analysts predict that Emergent Biosolutions Inc will post 1.98 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Los Angeles Capital Management & Equity Research Inc. Has $1.82 Million Position in Emergent Biosolutions Inc (EBS)” was first published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://www.dailypolitical.com/2018/11/20/los-angeles-capital-management-equity-research-inc-has-1-82-million-position-in-emergent-biosolutions-inc-ebs.html.

Emergent Biosolutions Profile

Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.

See Also: Insider Trading

Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions Inc (NYSE:EBS).

Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.